News

A Finnish population study shows that signs related to Alzheimer's disease may already be found in the brain in middle age.
Previous studies have concluded that early intervention in dementia cases can increase patients' treatment options and ...
The number of Americans diagnosed with Alzheimer’s each year is expected to double by 2060, with the majority of cases affecting women.
Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...
A Finnish population study shows that signs related to Alzheimer's disease may already be found in the brain in middle age.
The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to ...
Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technologyPrecli ...
SCIENTISTS have spent decades trying to understand what causes dementia. Is it alcohol? Obesity? Or are some of us simply ...
Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid ...
Neuroscientists have taken a major step toward detecting Alzheimer’s disease in its earliest stages—long before memory loss ...
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS, ...